Entry Into European And Asian Markets Will Unlock New Opportunities

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

08 May 25

Updated

28 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-75.6%

7D

12.5%

Loading

1Y

-75.6%

7D

12.5%

You can edit this narrative until Nov 29 6:10 PM. Then, changes will post as Updates.

Author's Valuation

US$9.6718.1% overvalued

AnalystConsensusTarget Fair Value

Shared on 28 Nov 25

RXST: Future Performance Will Hinge On Sustaining Outperformance Amid Lawsuit Uncertainty

Analysts have increased their price target for RxSight by $2 to $10, citing stronger than expected quarterly revenue performance and a favorable outlook for future estimates. Analyst Commentary Analysts have shared insights following the latest quarterly results for RxSight, highlighting both the optimistic outlook and areas of caution as the company navigates its growth trajectory.

Shared on 14 Nov 25

Fair value Increased 8.75%

RXST: Future Performance Will Depend On Sustained Revenue Execution And Demand Consistency

Analysts have increased their price target for RxSight to $9.67 from $8.89, citing strong quarterly revenue performance well above expectations and expressing confidence in future revenue estimates. Analyst Commentary Following RxSight's latest quarterly results, analysts have highlighted several factors influencing their revised outlook for the company’s valuation and future performance.

Shared on 10 Aug 25

Fair value Decreased 27%

RxSight’s consensus price target has been significantly reduced to $8.89 as analysts cite ongoing quarterly misses, slower customer adoption, plateauing utilization rates, and uncertainty around commercial strategy execution. Analyst Commentary Multiple bearish analysts cite consecutive quarterly misses and lowered guidance as primary concerns impacting RxSight's outlook.

AnalystConsensusTarget Fair Value

US$9.67

18.1% overvalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

3.81%

Medical Equipment revenue growth rate

8.27%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.75%

Calculation

US$20.99m

Earnings '28

x

24.77x

PE Ratio '28

=

US$520.05m

Market Cap '28

US$520.05m

Market Cap '28

/

43.05m

No. shares '28

=

US$12.08

Share Price '28

US$12.08 Share Price '28

Discounted to 2025 @ 7.75% p.a.

=

US$9.65

Fair Value '25